Karyopharm Therapeutics
KPTI · Nasdaq · United States
Share price · KPTI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when KPTI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026-56.5%
Nothing announced by KPTI that day or the session before.
- 2 Nov 2026-83.1%
- 28 Oct 2026+73.4%
Nothing announced by KPTI that day or the session before.
- 22 Oct 2026+28.7%
- 14 Oct 2026-26.3%
- 1 Oct 2026-29.0%
- 29 Sep 2026-25.6%
Nothing announced by KPTI that day or the session before.
- 31 Jul 2026-72.6%
- 20 Jul 2026-21.5%
- 15 May 2026-13.8%
Share of unusual movement by asset
For each asset, the share of KPTI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2027 (2)
Regulatory and conference events
(10)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $33M | $29M | $55M+ $10M short-term inv. | $67M-$25M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $35M | $34M | $91M+ $0 short-term inv. | $22M-$23M operating cash flow | report ↗ |
| 2025-Q3 | $44M | $31M | $38M+ $8.2M short-term inv. | $33M-$5.9M operating cash flow | report ↗ |
| 2025-Q2 | $38M | $33M | $39M+ $13M short-term inv. | $37M-$19M operating cash flow | report ↗ |
| 2025-Q1 | $30M | $35M | $39M+ $31M short-term inv. | $23M-$39M operating cash flow | report ↗ |
| 2024-Q3 | $39M | $36M | $73M+ $61M short-term inv. | $32M-$19M operating cash flow | report ↗ |
| 2024-Q2 | $43M | $38M | $85M+ $67M short-term inv. | —-$39M operating cash flow | report ↗ |
| 2024-Q1 | $33M | $35M | $31M+ $118M short-term inv. | $37M-$44M operating cash flow | report ↗ |
| 2023-Q3 | $36M | $36M | $45M+ $165M short-term inv. | $35M-$30M operating cash flow | report ↗ |
| 2023-Q2 | $38M | $31M | $82M+ $156M short-term inv. | $33M-$26M operating cash flow | report ↗ |
| 2023-Q1 | $39M | $32M | $86M+ $176M short-term inv. | $34M-$19M operating cash flow | report ↗ |
| 2022-Q3 | $36M | $31M | $73M+ $77M short-term inv. | $36M-$28M operating cash flow | report ↗ |
| 2022-Q2 | $40M | $44M | $84M+ $89M short-term inv. | $49M-$35M operating cash flow | report ↗ |
| 2022-Q1 | $48M | $42M | $155M+ $52M short-term inv. | $41M-$59M operating cash flow | report ↗ |
| 2021-Q3 | $38M | $46M | $140M+ $67M short-term inv. | $52M-$24M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $146M | $126M | $61M+ $3.2M short-term inv. | $49M-$75M operating cash flow | report ↗ |
For full-year 2025, Karyopharm reported total revenue of $146.1M, up 0.6% YoY, including U.S. XPOVIO net product revenue of $114.9M. R&D spend was $125.6M, down 12.3% YoY. Cash, cash equivalents, restricted cash and investments totaled $64.1M at December 31, 2025, compared to $109.1M at year-end 2024, and the company reported a full-year net loss of $196.0M.
Management guided full-year 2026 total revenue to $130M-$150M, including U.S. XPOVIO net product revenue of $115M-$130M, with R&D and SG&A expenses of $230M-$245M; existing liquidity is expected to fund current operating plans into the second quarter of 2026. Key clinical catalysts include top-line data from the Phase 3 SENTRY trial in myelofibrosis expected in March 2026, Phase 3 XPORT-EC-042 in endometrial cancer expected in mid-2026, and Phase 3 XPORT-MM-031 in multiple myeloma expected in the second half of 2026. The company also noted expanded global access for selinexor, with approvals in more than 50 countries.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $145M | $143M | $63M+ $46M short-term inv. | $19M-$127M operating cash flow | report ↗ |
| 2023-FY | $146M | $139M | $53M+ $139M short-term inv. | $36M-$93M operating cash flow | report ↗ |
| 2022-FY | $157M | $149M | $137M+ $143M short-term inv. | $41M-$150M operating cash flow | report ↗ |
| 2021-FY | $210M | $161M | $197M+ $38M short-term inv. | $31M-$107M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 21 sales ($351K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-16 | Abate Kristin · Chief Accounting Officer | Open-market sale | 4,788 | $0.34 | $2K | Form 4 |
| 2026-10-01 | Abate Kristin · Chief Accounting Officer | Open-market sale | 378 | $1.19 | $450 | Form 4 |
| 2026-09-01 | Abate Kristin · Chief Accounting Officer | Open-market sale | 19 | $2.02 | $38 | Form 4 |
| 2026-07-28 | Poulton Stuart · EVP, Chief Development Officer | Open-market sale | 189 | $7.10 | $1K | Form 4 |
| 2026-05-21 | Greene Barry E · director | Award / grant | 15,508 | — | — | Form 4 |
| 2026-05-21 | BOHLIN GAREN G · director | Award / grant | 15,508 | — | — | Form 4 |
| 2026-05-21 | Su Zhen · director | Award / grant | 15,508 | — | — | Form 4 |
| 2026-05-21 | Schor Chen · director | Award / grant | 15,508 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 76 reporting institutions held 18.0M shares ($91.2M, 79.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Commodore Capital LP | 1,950,000 | $10.9M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 1,917,354 | $10.7M |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,806,322 | $10.1M |
| 4 | Avidity Partners Management LP | 927,482 | $6.4M |
| 5 | GOLDMAN SACHS GROUP INC | 947,579 | $5.3M |
| 6 | Catalio Capital Management, LP | 897,709 | $5.0M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 739,745 | $4.1M |
| 8 | Ikarian Capital, LLC | 733,435 | $4.1M |
| 9 | Affinity Asset Advisors, LLC | 500,000 | $2.8M |
| 10 | Soleus Capital Management, L.P. | 440,000 | $2.5M |
| 11 | MILLENNIUM MANAGEMENT LLC | 420,571 | $2.3M |
| 12 | Boxer Capital Management, LLC | 302,536 | $1.7M |
| 13 | Davidson Kempner Capital Management LP | 300,000 | $1.7M |
| 14 | ACORN CAPITAL ADVISORS, LLC | 287,826 | $1.6M |
| 15 | Eversept Partners, LP | 276,174 | $1.5M |